Credit score: Anna Tarazevich from Pexels
Printed in Medical Most cancers Analysis, outcomes of a VHIO-led research underscore the potential of the RAD51 biomarker in tailoring remedy methods in sufferers with early breast most cancers.
“A key objective of research focused on early-stage breast cancer is to identify biomarkers that can select patients who might benefit from less aggressive treatments than chemotherapy and personalize therapeutic strategies,” stated Violeta Serra, Head of VHIO’s Experimental Therapeutics Group and corresponding writer of this research.
Developed in-house by Serra’s laboratory, a take a look at based mostly on the detection of the RAD51 protein as a useful biomarker of homologous recombination restore (HRR) is at the moment being validated within the stratification of sufferers with most cancers related to deficiency on this DNA injury restore (DDR) pathway.
The investigators evaluated the feasibility and capability of the RAD51 take a look at to foretell which sufferers with early-stage breast most cancers would possibly reply to neoadjuvant remedy. In collaboration with the German Breast Group (GBG), they analyzed tumor samples from the randomized GeparOla medical trial that in contrast pathological full response (pCR) charges with neoadjuvant remedy with PARP inhibitor olaparib versus remedy with carboplatin chemotherapy.
“The GeparOla trial included patients with early HER2-negative breast cancer who had homologous recombination deficiency, HRD. In this post hoc analysis, we evaluated if the RAD51 test could identify patients with different responses to neoadjuvant therapy in this pre-selected patient population,” stated Guillermo Villacampa, Head of VHIO’s Biostatistics Group and co-first writer of this current research.
“Of the 90 samples evaluable for RAD51 testing, 80% presented RAD51 protein levels correlating with functional HRD. The pCR rate in patients treated with the PARP inhibitor who had HRD by RAD51 was 66.7%. This decreased to 22.2% in patients without HRD by RAD51. The multivariable analysis, including clinicopathological factors, presence of tumor-infiltrating lymphocytes, and type of treatment, demonstrated that RAD51 maintained its prognostic capacity by showing a statistically significant association with pCR,” added Villacampa.
“These findings support the potential of the RAD51 test in tailoring treatment strategies in early-stage breast cancer,” stated Violeta Serra. “Future biomarker-driven studies, such as the RADIOLA study led by SOLTI which has been designed to validate RAD51 in advanced breast cancer, results of which are expected later this year, should consider this present data to refine stratification factors and improve patient selection,” concluded Judith Balmaña, Head of VHIO’s Hereditary Most cancers Genetics Group and a co-author of this current research.
Extra info:
Guillermo Villacampa et al, RAD51 testing in sufferers with early HER2-negative breast most cancers and homologous recombination deficiency: post-hoc evaluation of the GeparOla trial, Medical Most cancers Analysis (2024). DOI: 10.1158/1078-0432.CCR-24-3148
Offered by
Vall d’Hebron Institute of Oncology
Quotation:
RAD51 testing exhibits promise in personalised early breast most cancers remedy (2025, January 13)
retrieved 13 January 2025
from https://medicalxpress.com/information/2025-01-rad51-personalized-early-breast-cancer.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
